Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer
- Conditions
- Endometrial Cancer
- Registration Number
- NCT00030485
- Lead Sponsor
- National Cancer Institute (NCI)
- Brief Summary
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
PURPOSE: Phase II trial to determine the effectiveness of erlotinib in treating patients who have locally advanced and/or metastatic endometrial cancer.
- Detailed Description
OBJECTIVES:
* Determine the efficacy of erlotinib, in terms of response rate and duration of stable disease, in patients with locally advanced and/or metastatic carcinoma of the endometrium.
* Determine the toxicity of this drug in these patients.
* Determine the time to progression and duration of response in patients treated with this drug.
* Correlate objective tumor response with levels of epidermal growth factor receptor expression in patients treated with this drug.
OUTLINE: This is a multicenter study.
Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients are followed at 4 weeks. Patients with complete or partial response or stable disease are also followed every 3 months until relapse or death.
PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 12-18 months.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (8)
Princess Margaret Hospital
🇨🇦Toronto, Ontario, Canada
Cancer Care Ontario-London Regional Cancer Centre
🇨🇦London, Ontario, Canada
British Columbia Cancer Agency
🇨🇦Vancouver, British Columbia, Canada
Margaret and Charles Juravinski Cancer Centre
🇨🇦Hamilton, Ontario, Canada
Hopital Notre- Dame du CHUM
🇨🇦Montreal, Quebec, Canada
Tom Baker Cancer Center - Calgary
🇨🇦Calgary, Alberta, Canada
Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada
Kingston Regional Cancer Centre
🇨🇦Kingston, Ontario, Canada